Skip to main content
. Author manuscript; available in PMC: 2011 Dec 1.
Published in final edited form as: Am J Psychiatry. 2010 Oct 1;167(12):1489–1498. doi: 10.1176/appi.ajp.2010.10030318

Figure 2. The effects of potentially confounding variables on mGluR1α and RGS4 mRNA expression levels in schizophrenia subjects.

Figure 2

Sex, suicide, diagnosis of substance abuse or dependence current at the time of death, antidepressant medication use at time of death, use of benzodiazepines or sodium valproate at time of death, antipsychotic medication use at time of death, and history of cannabis use (THC; tetrahydrocannabinol) did not significantly affect mGluR1α mRNA or RGS4 mRNA expression levels. However, schizophrenia subjects may have a higher level of mGluR1α mRNA expression than schizoaffective disorder (SA) subjects (+11.5%; F(1,34)=4.42, p=.043) with no difference in RGS4 mRNA expression levels. Numbers within bars indicate the sample size for that subgroup of schizophrenia subjects.